UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 429, 2023

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-55453		45-2552528
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6320 Canoga Avenue, 15^thFloor

Woodland Hills, CA 91367

(Address of principal executive office)(Zip Code)

Registrant’s telephone number, including area code: (800) 489-4774

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On December 329, 2023, ~~the~~Endonovo ~~Company~~Therapeutics, ~~entered~~Inc. ~~into~~(“we”, a“us” ~~definitive~~or ~~Asset~~the ~~Purchase~~“Company”) ~~Agreement~~entered ~~with~~into ~~SofPulse,~~an ~~Inc., a Delaware corporation~~amendment (~~"SPI"~~the “Amendment”), to ~~acquire~~its ~~the~~May ~~SofPulse®~~2020 ~~Assets~~agreement ~~which~~with ~~represents~~Evermed ~~the~~Medical ~~technology,~~Enterprise ~~both~~Ltd ~~patented~~(“Evermed”) ~~and~~regarding ~~proprietary,~~the ~~inventories~~marketing ~~and~~of ~~contract rights relating to~~ the Company'’s SofPulse® ~~Electroceutical®~~ device asin ~~it relates to medical use~~Taiwan. The ~~Company~~ ~~has~~Amendment, ~~retained~~among ~~rights~~other tothings, ~~the~~establishes ~~non-medical~~performance ~~applications~~thresholds ofwhich ~~SofPulse®~~Evermed must ~~and~~meet ~~will~~to ~~continue~~maintain ~~the development of~~ its ~~tele-health business.~~exclusive ~~The~~rights ~~purchase~~in ~~price~~Taiwan under the ~~Asset Purchase~~ Agreement. ~~shall~~The beAmendment nosets ~~less~~forth ~~then~~quarterly ~~$50~~sales ~~Million~~thresholds ~~and~~for ~~shall~~a besix-year period ~~fixed~~beginning toApril ~~equal~~1, ~~the amount~~2024. ofThe athresholds ~~third~~increase ~~party~~during ~~evaluation of~~ the ~~SofPulse®~~six-year ~~Assets~~period ~~which~~from ~~will~~$8,400 bein ~~completed before~~ the ~~closing~~first ~~under~~quarter of the ~~Asset~~first ~~Purchase~~year ~~Agreement.~~to $502,856,000 ~~Million~~in of the ~~purchase~~last ~~price~~quarter ~~for~~of the ~~SofPulse®~~sixth ~~Assets~~year ~~will~~and betotal ~~paid~~$21,688,632 byfor the ~~issuance~~full ofsix ~~SPI~~years. ~~stock~~As toreported ~~the~~in ~~Company tentatively~~October ~~valued~~2023, ~~at $5 a share but to be adjusted to be equal to~~ the ~~per~~Taiwan Food ~~share~~and ~~price~~Drug inAdministration ~~SPI's IPO~~ (~~which may or may not ever occur~~“TFDA”), ~~and~~ the ~~balance~~regulatory todivision beof in the ~~form~~Ministry of ~~cash~~Health orand ~~note.~~Welfare ~~The~~(“MOHW”) has ~~Closing~~approved ~~under~~ the ~~Asset~~SofPulse® ~~Purchase~~device ~~Agreement~~for isadjunctive ~~subject~~treatment toof ~~shareholder approval~~pain ~~by the Company~~ and ~~other~~swelling ~~conditions.The~~(inflammation) ~~foregoing~~after issoft ~~only~~tissue asurgery. ~~summary~~We ~~of the Asset Purchase Agreement and the reader is~~cannot ~~referred~~guarantee tothat the ~~agreement,~~payments ~~which~~provided isfor anin ~~exhibit~~the toAmendment ~~this~~will ~~report~~actually ~~for~~be ~~its~~received ~~full~~by ~~terms and conditions~~us.

The foregoing is only a summary of the terms of the Amendment which is included as an exhibit to this report.

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements

	(a)	Financial Statements

	None

	(b)	Exhibits

		10.1 The Amendment.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

None

(b) Exhibits

	10.1	Asset Purchase Agreement
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~December~~January 43, ~~2023~~2024

	ENDONOVO THERAPEUTICS, INC.

	By:	/s/ Alan Collier
		Alan Collier
		Chief Executive Officer

Filing Compare · ENDONOVO THERAPEUTICS, INC.